BioCentury
ARTICLE | Clinical News

Gazyva regulatory update

November 16, 2015 8:00 AM UTC

FDA accepted and granted Priority Review to an sBLA from Roche’s Genentech unit for Gazyva obinutuzumab to treat patients with follicular lymphoma who relapsed after or are refractory to a rituximab-c...